United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 15,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $407.32, for a total transaction of $6,109,800.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $400.87 on Wednesday. The business has a fifty day moving average of $360.91 and a 200-day moving average of $325.71. The firm has a market cap of $17.90 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.20 and a beta of 0.56. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the firm earned $5.38 EPS. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. The Goldman Sachs Group increased their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. SG Americas Securities LLC increased its stake in shares of United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after acquiring an additional 9,133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares during the period. Comerica Bank boosted its position in shares of United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares in the last quarter. Tri Locum Partners LP acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $15,959,000. Finally, QRG Capital Management Inc. increased its position in shares of United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after buying an additional 1,692 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.